COST-EFFECTIVENESS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN AUSTRALIA

被引：0
|
作者：
Tilden, D. [1 ]
Germanos, P. [2 ]
Gordon, J. [2 ]
Tocchini, L. [1 ]
Monz, B. [3 ]
机构：
[1] THEMA Consulting Pty Ltd, Pyrmont, NSW, Australia
[2] Boehringer Ingelheim Pty Ltd, N Ryde, NSW, Australia
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.781
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A375 / A375
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
  • [2] Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients
    Lip, Gregory Y.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Liu, Larry Z.
    Lawrence, John
    Dorian, Paul
    [J]. CIRCULATION, 2014, 130
  • [3] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [4] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [5] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [6] COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION - A MULTINATIONAL STUDY
    Asukai, Y.
    Maniadakis, N.
    Carcedo, D.
    Lukac, M.
    Evers, T.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A285 - A285
  • [7] Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
    Hersi, Ahmad S.
    Osenenko, Katherine M.
    Kherraf, Sid Ahmed
    Aziz, Ayman Abdel
    Sambrook, Robert Joseph
    [J]. ANNALS OF SAUDI MEDICINE, 2019, 39 (04) : 265 - 278
  • [8] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [9] STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION: SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES
    Costa, S.
    Ramos, J. C.
    Braga, A. C.
    Pereira, J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A531 - A531
  • [10] The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
    van Hulst, Marinus
    Stevanovic, Jelena
    Jacobs, Maartje S.
    Tieleman, Robert G.
    Kappelhoff, Bregt
    Postma, Maarten J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (01) : 38 - 46
12345